Recruiting
Phase 2

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Sponsor:

Teclison Ltd.

Code:

NCT04701476

Conditions

Colorectal Cancer; Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

TATE and pembrolizumab

TAS-102 pill

Regorafenib Pill

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information